Search Results 361-370 of 17352 for alopecia
Experienced resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If patient underwent major surgery or ...
... alopecia, vitiligo, and the laboratory values defined in the inclusion criteria: Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case ...
Toxicities related to prior therapy must have returned to Grade 1 or less, except for alopecia. ... alopecia) not requiring systemic treatment, or ...
... . VID-20096965. Home; Rectal Cancer Surgery Outcomes Enhanced with Colorectal Surgeons David Etzioni. Double your impact on cancer!
... . VID-20164181. Home; Arizona Young Volunteers. Double your impact on cancer! Give Now. Make a gift before July 31 and it can be doubled in impact ...
... alopecia and Grade 2 peripheral neuropathy. For France only: A subject will be eligible for inclusion in this study only if either affiliated to or a ...
prior therapies (excluding alopecia, neuropathy, and nail changes). - Clinical laboratory values as specified below within 14 days before the first dose of
Lichen sclerosus, Lichen planus, Skin wrinkles, Vulvar disorder, Acne, Alopecia areata, Melasma, Age spots, UV skin damage, Rosacea, Canker sores, Actinic ...
... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Vulvar skin disorder, Breast skin change, Rosacea, Pigmentation disorder ...
Patients with vitiligo or alopecia; ... Any unresolved toxicity National Cancer Institute (NCI) CTCAE v 5.0 Grade ≥ 2 from previous anticancer therapy, with the ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.